{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-058156","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.852116+00:00","generated_at":"2026-06-08T23:46:49.773729+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Syndax reports Q3 net loss $0.73/sh, initiates revumenib NDA in R/R KMT2Ar leukemia","bullets":["Net loss $51.1M ($0.73/sh) vs $35.4M ($0.58/sh) YoY; cash $379.3M as of Sep 30, 2023.","NDA submission initiated for revumenib in R/R KMT2Ar acute leukemia under FDA RTOR; completion expected by year-end 2023.","Final Phase 1 mNPM1 data: 36% CR/CRh (5/14); 100% of CR/CRh patients MRD-negative; responses durable >22 months.","Pivotal AUGMENT-101 met primary endpoint: 23% CR/CRh in KMT2Ar acute leukemia; median duration 6.4 months.","Full-year 2023 expense guidance reduced: R&D now $160-165M (prev $160-175M); total OpEx $225-230M (prev $225-240M)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-058156","json":"https://secwatch.observer/filing/0000950170-23-058156.json","markdown":"https://secwatch.observer/filing/0000950170-23-058156.md","text":"https://secwatch.observer/filing/0000950170-23-058156.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000095017023058156/0000950170-23-058156-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000095017023058156/sndx-20231102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T23:46:49.773729+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a1d88a4b6e0dc681c5e9f2df9bcb205d2257595b","claim":"Syndax Pharmaceuticals Inc reported financial results for the quarter ended September 30, 2023.","evidence_excerpt":"On November 2, 2023, Syndax Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000095017023058156/0000950170-23-058156-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}